Patents by Inventor Scott Gangloff

Scott Gangloff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10696735
    Abstract: Combinations of different chromatography modalities with particularly refined conditions significantly reduce acid charge variants in a preparation of monoclonal antibodies. The process for reducing acid charge variants utilizes a combination of anion exchange and hydrophobic interaction chromatography, followed by cation exchange chromatography polishing, whereby the levels of acidic or basic charge species of the monoclonal antibodies may be modulated to a desired level.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: June 30, 2020
    Assignee: Outlook Therapeutics, Inc.
    Inventors: Chris Yonan, Christine Caroselli, Wiphusanee Dendamrongvit, Scott Gangloff
  • Publication number: 20190161543
    Abstract: Alterations in bioreactor cell culture feeding to an extended or continuous feed following an initial period of no feeding reduces the level of high molecular weight, acid charge, and fragment species of monoclonal antibodies expressed in the culture, and enhances the level of afucosylated species of monoclonal antibodies expressed in the culture. Regular fucose infusions following an initial period of no feed media infusion reduces the level of afucosylated species of monoclonal antibodies expressed in the culture. Cell culture manipulation may be used to modulate the level of species of monoclonal antibodies.
    Type: Application
    Filed: January 5, 2017
    Publication date: May 30, 2019
    Inventors: Marc SANTORO, Kevin John JOSE, Sri MADABHUSHI, Scott GANGLOFF
  • Publication number: 20190048070
    Abstract: Alterations in bioreactor cell culture feeding to an extended or continuous feed following an initial period of no feeding reduces the level of high molecular weight, acid charge, and fragment species of monoclonal antibodies expressed in the culture, and enhances the level of afucosylated species of monoclonal antibodies expressed in the culture. Regular fucose infusions following an initial period of no feed media infusion reduces the level of afucosylated species of monoclonal antibodies expressed in the culture. Cell culture manipulation may be used to modulate the level of species of monoclonal antibodies.
    Type: Application
    Filed: January 5, 2017
    Publication date: February 14, 2019
    Inventors: Marc SANTORO, Kevin John JOSE, Sri MADABHUSHI, Scott GANGLOFF
  • Publication number: 20190016753
    Abstract: Charge variants of a recombinantly expressed antibody population may be separated both from the main antibody molecule and from each other. Separation and isolation of charge variants may proceed via a combined modulation of salt concentration and pH during charge variant elution from a cation exchange support. Isolated charge variants may be assessed for their contribution to the potency of the overall antibody preparation. The make-up of an antibody preparation, at least in terms of the proportion of charge variants and of the main antibody can thus be controlled, for example, for biosimilar matching or for improving potency of the preparation.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 17, 2019
    Inventors: Eun JANG, Pradeep PANDEY, Kaushal JERAJANI, Scott GANGLOFF
  • Publication number: 20180009876
    Abstract: Combinations of different chromatography modalities with particularly refined conditions significantly reduce acid charge variants in a preparation of monoclonal antibodies. The process for reducing acid charge variants utilizes a combination of anion exchange and hydrophobic interaction chromatography, followed by cation exchange chromatography polishing, whereby the levels of acidic or basic charge species of the monoclonal antibodies may be modulated to a desired level.
    Type: Application
    Filed: January 21, 2016
    Publication date: January 11, 2018
    Inventors: Chris YONAN, Christine CAROSELLI, Wiphusanee DENDAMRONGVIT, Scott Gangloff
  • Publication number: 20080070280
    Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, illustratively, but not limited to, fed-batch cell cultures. The methods comprise feeding the cells with D-galactose, preferably with feed medium containing D-galactose, preferably daily, to sustain a sialylation effective level of D-galactose in the culture for its duration, thus increasing sialylation of the produced proteins. The methods can also comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. The cell culture processes of the invention involving two or more temperature shifts sustain a high cell viability, and can allow for an extended protein production phase. The methods can also comprise the delayed addition of polyanionic compound at a time after inoculation.
    Type: Application
    Filed: October 22, 2007
    Publication date: March 20, 2008
    Inventors: Bernhard Schilling, Scott Gangloff, Dharti Kothari, Kirk Leister, Linda Matlock, Stephen Zegarelli, Christoph Joosten, Jonathan Basch, Sivakesava Sakhamuri, Steven Lee
  • Patent number: 7332303
    Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, illustratively, but not limited to, fed-batch cell cultures. The methods comprise feeding the cells with D-galactose, preferably with feed medium containing D-galactose, preferably daily, to sustain a sialylation effective level of D-galactose in the culture for its duration, thus increasing sialylation of the produced proteins. The methods can also comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. The cell culture processes of the invention involving two or more temperature shifts sustain a high cell viability, and can allow for an extended protein production phase. The methods can also comprise the delayed addition of polyanionic compound at a time after innoculation.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: February 19, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bernhard M. Schilling, Scott Gangloff, Dharti Kothari, Kirk Leister, Linda Matlock, Stephen G. Zegarelli, Christoph E. Joosten, Jonathan D. Basch, Sivakesava Sakhamuri, Steven S. Lee
  • Publication number: 20050084933
    Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, illustratively, but not limited to, fed-batch cell cultures. The methods comprise feeding the cells with D-galactose, preferably with feed medium containing D-galactose, preferably daily, to sustain a sialylation effective level of D-galactose in the culture for its duration, thus increasing sialylation of the produced proteins. The methods can also comprise at least two temperature shifts performed during the culturing period, in which the temperature is lower at the end of the culturing period than at the time of initial cell culture. The cell culture processes of the invention involving two or more temperature shifts sustain a high cell viability, and can allow for an extended protein production phase. The methods can also comprise the delayed addition of polyanionic compound at a time after innoculation.
    Type: Application
    Filed: December 18, 2003
    Publication date: April 21, 2005
    Inventors: Bernhard Schilling, Scott Gangloff, Dharti Kothari, Kirk Leister, Linda Matlock, Stephen Zegarelli, Christoph Joosten, Jonathan Basch, Sivakesava Sakhamuri, Steven S. Lee